(Q38421891)

2 September 2017

title

Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? (English)

1 reference

2 September 2017

0 references

1 reference

Jerker Jonsson

2

0 references

Elizabeth V Arkema

object named as

Elizabeth V Arkema

1

0 references

Judith Bruchfeld

4

object named as

Judith Bruchfeld

1 reference

2 September 2017

Eva Baecklund

3

1 reference

2 September 2017

Nils Feltelius

5

1 reference

2 September 2017

Johan Askling

6

1 reference

2 September 2017

ARTIS Study Group

7

1 reference

2 September 2017

language of work or name

English

0 references

publication date

7 March 2014

1 reference

Annals of the Rheumatic Diseases

2 September 2017

published in

1 reference

2 September 2017

volume

74

1 reference

2 September 2017

issue

6

1 reference

2 September 2017

page(s)

1212-1217

1 reference

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

Mycobacterial diseases and antitumour necrosis factor therapy in USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

Assessing the safety of biologic agents in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

Risk of mycobacterial infections associated with rheumatoid arthritis in Ontario, Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204960

10.1136/ANNRHEUMDIS-2013-204960

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference